142 related articles for article (PubMed ID: 36480802)
1. Implementation and Evaluation of a Collaborative, Pharmacy-Based Hepatitis C and HIV Screening Program.
Klepser DG; Klepser ME; Peters PJ; Hoover KW; Weidle PJ
Prev Chronic Dis; 2022 Dec; 19():E83. PubMed ID: 36480802
[TBL] [Abstract][Full Text] [Related]
2. Innovating the Model for Student Pharmacists to Increase Access to Hepatitis C Testing (Project IMPACT).
Januszka J; Notarianni V; Devenny E; Harris E
J Am Pharm Assoc (2003); 2023; 63(4):1217-1221. PubMed ID: 37037394
[TBL] [Abstract][Full Text] [Related]
3. Pharmacist-initiated hepatitis C virus screening in a community pharmacy to increase awareness and link to care at the medical center.
Isho NY; Kachlic MD; Marcelo JC; Martin MT
J Am Pharm Assoc (2003); 2017; 57(3S):S259-S264. PubMed ID: 28506379
[TBL] [Abstract][Full Text] [Related]
4. Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project.
Dong BJ; Lopez M; Cocohoba J
J Am Pharm Assoc (2003); 2017; 57(4):510-515.e2. PubMed ID: 28602784
[TBL] [Abstract][Full Text] [Related]
5. Time and motion study of hepatitis C virus point-of-care testing in community pharmacies.
Beuschel T; Gootee E; Jordan M; Sikkenga T; Klepser DG; Holmquist H; de Voest A; Klepser ME
J Am Pharm Assoc (2003); 2023; 63(1):435-439. PubMed ID: 36463010
[TBL] [Abstract][Full Text] [Related]
6. Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy.
Brewer A; Hanna C; Eckmann L; Schadler A; Divine H
J Am Pharm Assoc (2003); 2018; 58(4S):S69-S72.e1. PubMed ID: 30006188
[TBL] [Abstract][Full Text] [Related]
7. Pharmacist Comfort and Awareness of HIV and HCV Point-of-Care Testing in Community Settings.
Min AC; Andres JL; Grover AB; Megherea O
Health Promot Pract; 2020 Sep; 21(5):831-837. PubMed ID: 31257939
[TBL] [Abstract][Full Text] [Related]
8. Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky.
Duong M; Delcher C; Freeman PR; Young AM; Cooper HLF
J Rural Health; 2022 Jan; 38(1):93-99. PubMed ID: 33666274
[TBL] [Abstract][Full Text] [Related]
9. Pharmacist-led HIV and hepatitis C point-of-care testing and risk mitigation counseling in individuals experiencing homelessness.
Kherghehpoush S; McKeirnan KC
Explor Res Clin Soc Pharm; 2021 Mar; 1():100007. PubMed ID: 35479505
[TBL] [Abstract][Full Text] [Related]
10. Expanding access to HIV testing through Canadian community pharmacies: findings from the APPROACH study.
Kelly DV; Kielly J; Hughes C; Gahagan J; Asghari S; Hancock S; Burt K; Smyczek P; Charlton C; Nguyen H
BMC Public Health; 2020 May; 20(1):639. PubMed ID: 32380978
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot.
Stämpfli D; Imfeld-Isenegger TL; Hersberger KE; Messerli M
BMC Infect Dis; 2023 Jun; 23(1):384. PubMed ID: 37286975
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C screening in a community pharmacy setting: Patient perspective.
Pegump KN; Nichols RE; Polgreen LA; Veach SR; Crowner AB; Witry MJ
J Am Pharm Assoc (2003); 2023; 63(4S):S78-S82. PubMed ID: 36804712
[TBL] [Abstract][Full Text] [Related]
13. HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.
Weidle PJ; Lecher S; Botts LW; Jones L; Spach DH; Alvarez J; Jones R; Thomas V
J Am Pharm Assoc (2003); 2014; 54(5):486-92. PubMed ID: 25216878
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and outcomes of a hepatitis C screening programme in community pharmacies.
Gauld N; Perry J; Jackson C; Gane E
N Z Med J; 2020 Nov; 133(1525):74-83. PubMed ID: 33223550
[TBL] [Abstract][Full Text] [Related]
15.
Byrne C; Radley A; Inglis SK; Beer LJZ; Palmer N; Pham MD; Healy B; Doyle JS; Donnan P; Dillon JF
BMJ Open; 2020 Aug; 10(8):e036501. PubMed ID: 32868356
[TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
17. Pharmacists' Opinions on the Implementation of HIV and HepC Point-of-Care-Testing in a U.S. Pharmacy Chain.
So E; Brands M; Suomala E; Ogden B; Riss J; Cernasev A; Schommer J
Innov Pharm; 2019; 10(1):. PubMed ID: 34007531
[TBL] [Abstract][Full Text] [Related]
18. The role of community pharmacies in the HIV and HCV care continuum.
Kherghehpoush S; McKeirnan KC
Explor Res Clin Soc Pharm; 2023 Mar; 9():100215. PubMed ID: 36938123
[TBL] [Abstract][Full Text] [Related]
19. Point-of-care HIV and hepatitis screening in community pharmacies: a quantitative and qualitative study.
Figueira I; Teixeira I; Rodrigues AT; Gama A; Dias S
Int J Clin Pharm; 2022 Oct; 44(5):1158-1168. PubMed ID: 36098836
[TBL] [Abstract][Full Text] [Related]
20. Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
Rowan SE; Kamis KF; Beum R; Bryan K; Gawenus L; Colon Sanchez D; Hurley H
J Infect Dis; 2020 Sep; 222(Suppl 5):S384-S391. PubMed ID: 32877565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
